Project Grant R01CA293806
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$586K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Oregon, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $170,000.00 to Providence Health & Services - Oregon to develop a novel positron emission tomography (PET) radiotracer for in vivo imaging of transforming growth factor beta (TGFβ). The research aims to assess the efficacy of the 64Cu-FC:TBRII radiotracer, including dose titration, blocking studies, and comparative analysis of in vivo PET standardized uptake values...
This $676,567 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to The Regents of the University of California, San Francisco (UCSF). The grant supports a 5-year research project to systematically evaluate the effectiveness of a transforming growth factor beta (TGFβ)-targeted radiopharmaceutical therapy (RPT) as a potential tumor-agnostic cancer treatment. The project aims to radiolabel a validated TGFβ-neutralizing...
This $577,818 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to develop new therapeutic combinations to boost the "abscopal effect" and improve clinical outcomes for patients with advanced cancers. The award supports research at Mayo Clinic to investigate the role of the immune checkpoint molecule B7-H3 in mediating tumor immune evasion, with the goal of overcoming resistance to radiotherapy. The...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $662,516 to The General Hospital Corporation (Massachusetts General Hospital) to evaluate how fractionated radiation affects drug delivery within the tumor microenvironment, and to test whether long-circulating chemotherapy can combine with standard chemoradiotherapy to safely improve treatment responses. The 5-year project will utilize in vivo imaging,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,829 to the University of Washington to develop a framework for guiding re-irradiation treatment plans. The research aims to: 1) quantify the evolution of normal tissue damage and recovery after radiation therapy using imaging biomarkers, and 2) explore the feasibility of personalizing re-irradiation based on the observed normal tissue response from the first radiation...
This $127,049.00 federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) aims to define the functional and spatial properties of tumor-specific tumor-infiltrating CD8 T cells. Specifically, the project will:
Generate patient-derived xenograft (PDX) murine models of 3 melanoma patient tumors to test the required diversity of T cell receptors (TCRs) from tumor-infiltrating T cells needed to exert immune pressure on a heterogeneous tumor like...
This federal Project Grant award provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to develop a novel therapeutic approach for overcoming radiation resistance in triple negative breast cancer (TNBC). The $512,582 award supports research to investigate the mechanism by which vascular endothelial growth factor (VEGF) signaling through neuropilin-2 (NRP2) contributes to radiation resistance, and to test whether targeted inhibition of...
The National Cancer Institute (NCI) awarded a $1,181,452 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Johns Hopkins University. The award, spanning from June 1, 2024 to May 31, 2029, aims to develop and translate a prototype system for 3D tumor tracking using scattered X-ray photons. The project will pursue four specific aims: 1) developing a prototype hardware system to image the tumor region, 2) developing a software system for data processing...
This $452,544 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) to target regulatory T cells (Tregs) in the solid tumor microenvironment. The research aims to enhance the efficacy of T cell-based immunotherapies for solid tumors by inhibiting the immunosuppressive effects of Tregs. Specifically, the project will investigate how modulating the...
This National Cancer Institute (NCI) Project Grant Award under the Cancer Treatment Research Program (CFDA 93.395) provides $633,355 to Northwestern University to conduct research on sustaining the metabolic fitness of effector CD8+ T cells for enhanced anti-tumor immunity. The research aims to define the metabolic and cellular effects of sustaining the glutathione-glutathione peroxidase 4 (GSH-GPX4) axis while inhibiting the adenosine A2A receptor (A2AR) signaling pathway in effector T...